# Bortezomib in Treating Children With Advanced Solid Tumors

> **NCT00021216** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Unspecified Childhood Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** bortezomib
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00021216
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-12
- **Final completion:** 2005-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00021216

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00021216, "Bortezomib in Treating Children With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00021216. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*